FCGR3A抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P08431(FCGR3A Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08431(FCGR3A Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

FCGR3A (Fc gamma receptor IIIa), also known as CD16a, is a cell-surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells, macrophages, and dendritic cells. As a low-affinity receptor for the Fc region of IgG antibodies, FCGR3A plays a critical role in antibody-dependent cellular cytotoxicity (ADCC), a mechanism by which immune cells recognize and eliminate antibody-coated pathogens or malignant cells. This receptor binds to immune complexes, triggering intracellular signaling pathways that activate cytotoxic responses, cytokine release, and phagocytosis.

Antibodies targeting FCGR3A are widely used in research and therapeutics. In clinical settings, therapeutic monoclonal antibodies (e.g., rituximab, trastuzumab) rely on FCGR3A engagement to enhance effector cell activity against cancer cells. Conversely, anti-FCGR3A antibodies can also block receptor function to modulate immune responses in autoimmune diseases. Genetic polymorphisms in FCGR3A, particularly the F158V variant, influence receptor affinity for IgG and correlate with differential clinical outcomes in antibody-based therapies.

Research on FCGR3A antibodies continues to advance personalized medicine, particularly in oncology and immunotherapy. Their dual role as therapeutic agents and experimental tools underscores their importance in understanding immune regulation and optimizing treatments for diseases like cancer, infections, and autoimmune disorders.